Dr Lawrence Schaffzin, MD in Cheltenham, PA - Ophthalmology

Dr Lawrence Schaffzin, MD is a Ophthalmology physician based in Cheltenham, Pennsylvania. Dr Lawrence Schaffzin is licensed to practice in New Jersey (license number 25MA05297300) and his current practice location is 404 Croyden Rd, Cheltenham, Pennsylvania. He can be reached at his office (for appointments etc.) via phone at (215) 805-4078.

NPI number for Dr Lawrence Schaffzin is 1265538037 and his current mailing address is 225 Sunset Rd, Willingboro, New Jersey. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1265538037.

Contact Information

	Dr Lawrence Schaffzin, MD
	404 Croyden Rd, Cheltenham, PA 19012-1612
	(215) 805-4078
	Not Available

Physician's Profile

Full Name	Dr Lawrence Schaffzin
Gender	Male
Speciality	Ophthalmology
Location	404 Croyden Rd, Cheltenham, Pennsylvania
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1265538037
Provider Enumeration Date: 09/16/2006
Last Update Date: 09/21/2023

Medical Identifiers

Medical identifiers for Dr Lawrence Schaffzin such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1265538037	NPI	-	NPPES
9104704	Medicaid	NJ

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	25MA05297300 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Lawrence Schaffzin is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Lawrence Schaffzin, MD 225 Sunset Rd, Willingboro, NJ 08046-1109 Ph: (609) 877-2800	Dr Lawrence Schaffzin, MD 404 Croyden Rd, Cheltenham, PA 19012-1612 Ph: (215) 805-4078

News Archive

Parents of children with ASD turn to evidence-based behavioral treatment methods

One of the most common initial red flags reported by parents of children with autism is that they suspect their child may be deaf because he or she no longer responds to his or her name, and does not look at them when they speak. However, the lack of response or eye contact can point to an Autism Spectrum Disorder. In fact, many children on the autism spectrum do not demonstrate typical language skills and social behavior, or even lose language or social skills they once had.

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

Arsanis closes Series A financing for $10 million

Arsanis, Inc, a recently founded biotechnology company dedicated to the development of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area.

Innovation holds the key for solving healthcare's dilemmas, says Eli Lilly

In an address to the American Chamber of Commerce in Germany today, John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, said that innovation holds the key to solving one of healthcare's thorniest dilemmas: how to improve quality and access while controlling costs.

Dr Lawrence Schaffzin, MD - Ophthalmology in Cheltenham, PA